MCL

Linda Hasadsri, M.D., Ph.D., explains carrier screening at Mayo Clinic Laboratories. Using targeted genotyping, our three focused panels evaluate genes associated with cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, to provide clear answers on reproductive risks and to guide decision-making.

Utilizing testing capabilities of two separate laboratory facilities, Mayo Clinic Laboratories’ new serotonin release assay (SRA) is a gold-standard test supported by decades of clinical hematopathologic experience and advanced mass spectrometry testing.

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.

Since overcoming a life-threatening diagnosis five years ago, Jim Smith has embraced life. But each time he travels to Mayo Clinic for follow-up laboratory testing, a well of emotions rises up to remind him of life’s fragility. Thankfully, through streamlined, accurate testing and top-notch clinical care, those feelings are generally short-lived.

In this month's "Hot Topic," Kevin Halling, M.D., Ph.D., discusses new next generation sequencing testing for various tumor types and the rationale for the enhancements that were made; reviews gene additions that are now available in each of the panels; and briefly speaks about the work that was done to validate cytology specimens for use in the subpanels.

Due to the Thanksgiving holiday (recognized on Thursday, November 24th), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered. To ensure that your specimen vitality and turnaround times are not affected, plan ahead.

This list includes updates posted to mayocliniclabs.com during the month of October.

In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.

In the inaugural episode of the "Leveraging the Laboratory" podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by outreach colleagues Brianne Newton and Ellen Dijkman Dulkes. They discuss their laboratory backgrounds, the history and importance of laboratory outreach, and how their work can support the growth of hospital laboratories.

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.

In this month's "Hot Topic," David Viswanatha, M.D., discusses updates to Mayo Clinic's next-generation sequencing (NGS) for myeloid neoplasm evaluation, involving new test targets, the rationale for new genetic regions, alignments with the World Health Organization (WHO) guidelines and germline predisposition targets.

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Justin Juskewitch, M.D., Ph.D., and Andrew Norgan, M.D., Ph.D., both assistant professors of laboratory medicine and pathology at Mayo Clinic, to talk about informatics for the pathologist.